home / stock / bctxw / bctxw quote
Last: | $0.2099 |
---|---|
Change Percent: | 15.17% |
Open: | $0.1633 |
Close: | $0.2099 |
High: | $0.2255 |
Low: | $0.1605 |
Volume: | 13,800 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.2099 | $0.1633 | $0.2099 | $0.2255 | $0.1605 | 13,800 | 07-26-2024 |
$0.1925 | $0.1899 | $0.1925 | $0.2256 | $0.156249 | 205,243 | 07-25-2024 |
$0.19 | $0.1444 | $0.19 | $0.19076 | $0.1433 | 151,404 | 07-24-2024 |
$0.1599 | $0.1435 | $0.1599 | $0.16 | $0.1433 | 52,079 | 07-23-2024 |
$0.15165 | $0.15 | $0.15165 | $0.17875 | $0.1406 | 184,081 | 07-22-2024 |
$0.1686 | $0.15 | $0.1686 | $0.1859 | $0.14 | 306,450 | 07-19-2024 |
$0.15 | $0.15 | $0.15 | $0.164188 | $0.1274 | 38,276 | 07-18-2024 |
$0.15 | $0.143 | $0.15 | $0.165 | $0.1406 | 36,849 | 07-17-2024 |
$0.14 | $0.14 | $0.14 | $0.1687 | $0.1235 | 237,254 | 07-16-2024 |
$0.14 | $0.125 | $0.14 | $0.165 | $0.111 | 325,297 | 07-15-2024 |
$0.130005 | $0.1411 | $0.130005 | $0.1411 | $0.1055 | 501,225 | 07-12-2024 |
$0.156248 | $0.1995 | $0.156248 | $0.2 | $0.1357 | 314,756 | 07-11-2024 |
$0.184 | $0.2 | $0.184 | $0.23 | $0.1803 | 101,796 | 07-10-2024 |
$0.2034 | $0.24 | $0.2034 | $0.25 | $0.18 | 343,245 | 07-09-2024 |
$0.2492 | $0.2399 | $0.2492 | $0.2499 | $0.203101 | 322,815 | 07-08-2024 |
$0.2199 | $0.1831 | $0.2199 | $0.2499 | $0.1831 | 303,711 | 07-05-2024 |
$0.2186 | $0.235 | $0.2186 | $0.25 | $0.1841 | 179,840 | 07-04-2024 |
$0.2186 | $0.235 | $0.2186 | $0.25 | $0.1841 | 179,840 | 07-03-2024 |
$0.24 | $0.235 | $0.24 | $0.2621 | $0.1752 | 210,059 | 07-02-2024 |
$0.2689 | $0.2419 | $0.2689 | $0.2699 | $0.2131 | 173,794 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Warrant Company Name:
BCTXW Stock Symbol:
NASDAQ Market:
BriaCell Therapeutics Corp. Warrant Website:
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients Therapy well-tolerate...
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...